Array Biopharma, Inc. (ARRY) Posts Q4 Loss of 9c/Share, Narrower than Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.39 -4.78%
EPS Growth %: -70.0%
Financial Fact:
Comprehensive loss: -28.6M
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -70.0%
Financial Fact:
Comprehensive loss: -28.6M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $21.45 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Affle agrees to acquire Perion Network for ~$420 million
- Citi raises Clean Harbors price target to $379 from $378
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
